AU Patent

AU2013259779B2 — N-ethyl-4-hydroxyl-1-methyl-5- (methyl(2,3,4,5,6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1,2-dihydroquinoline-3-carboxamide

Assigned to Teva Pharmaceutical Industries Ltd · Expires 2017-06-08 · 9y expired

What this patent protects

The subject invention provides pharmaceutical compositions Containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1 -methyl-5- (methyl (2, 3,4,5, 6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1, 2- dihydroquinoline- 3 -carbox…

USPTO Abstract

The subject invention provides pharmaceutical compositions Containing laquinimod or a pharmaceutically acceptable salt thereof, an isolated compound of N-ethyl-4-hydroxyl-1 -methyl-5- (methyl (2, 3,4,5, 6-pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1, 2- dihydroquinoline- 3 -carboxamide or a salt thereof, compositions containing N-ethyl-4-hydroxyl-1-methyl-5- (methyl (2,3,4,5,6- pentahydroxyhexyl) amino) -2-oxo-N-phenyl-1, 2-dihydroquinoline-3-carboxamide and methods of preparing the same.

Drugs covered by this patent

Patent Metadata

Patent number
AU2013259779B2
Jurisdiction
AU
Classification
—
Expires
2017-06-08
Drug substance claim
No
Drug product claim
No
Assignee
Teva Pharmaceutical Industries Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.